US20070196823A1

US20070196823A1 - Surrogate markers for viral infections and other inflammatory responses

Info

Publication number: US20070196823A1
Application number: US11/622,124
Authority: US
Inventors: Thomas Hansen; Kathleen Austin; Alberto van Olphen; Lea Rempel
Original assignee: University of Wyoming
Current assignee: University of Wyoming
Priority date: 2006-01-11
Filing date: 2007-01-11
Publication date: 2007-08-23
Also published as: US20100240027A1; US8889845B2; WO2007082259A3; WO2007082259A2

Abstract

Compositions and methods for the detection, diagnosis and treatment of BVDV and other viruses are provided.

Description

This application claims priority to U.S. provisional Application No. 60/757,965 filed Jan. 11, 2006, the entire contents of which are incorporated by reference herein.
Pursuant to 35 U.S.C. Section 202(c), it is acknowledged that the United States Government has certain rights in the invention described herein, which was made in part with funds from the USDA/CSREES, grant numbers 2004-35204-14916 and 2004-35204-17005.

FIELD OF THE INVENTION

This invention relates to the field of molecular biology and virology. More specifically, the present invention provides materials and methods for the diagnosis and staging of bovine viral diarrhea virus (BVDV).

BACKGROUND OF THE INVENTION

Several publications and patent documents are cited throughout this application in order to more fully describe the state of the art to which this invention pertains. The disclosure of each of these citations is incorporated by reference herein.
Bovine viral diarrhea virus (BVDV) costs the United States cattle industry more than 400 million dollars per year. The pathogenesis of BVDV infection has features that are unique to this virus and vary with the time of infection, virulence of the viral strain, and age of the animals at the time of infection.
When the infection occurs after 150 days of gestation (post-development of the immune system) or after birth, including adult animals, the infection is referred to as acute infection. The clinical manifestation of acute infections with BVDV range from sub-clinical or unapparent infections to embryonic death, abortions, stillborn, malformed or slow growing calves.
Certain strains of BVDV can cause a hemorrhagic syndrome with high morbidity and moderate mortality in adult animals. Acutely infected animals usually recover and eliminate the virus within 10 to 14 days post infection.
Animals vaccinated with modified live vaccines against BVDV have an immune response similar to the one induced by natural, acute infection. In contrast, infection of the fetus during the first 150 days of gestation, when the immune system has not yet developed, can lead to the generation of persistently infected (PI) calves. Some of these PI calves die soon after birth, but others live for relatively long periods of time without showing any clinical signs. PI animals cannot eliminate the infecting BVDV from their system, and continuously release high amounts of virus in their bodily secretions and excretions, making them a continuous source of infection within the herd and potentially to other herds as well. Furthermore, nursing PI calves can acutely infect their mothers and other normal nursing calves, which in turn infect their own mothers while they are pregnant, producing a new cycle of infection and eventually more PI calves.
Mucosal disease, an uncommon but fatal complication observed in PI calves, occurs when the virus mutates or the animal is superinfected with an antigenically related BVDV virus. Current vaccines are relatively inefficient in preventing fetal infections, therefore the identification and elimination of PI animals is essential to any successful program for control or eradication of BVDV.
Currently available tests for the detection of PI animals are based on the identification of the viral antigen in a blood or tissue sample (most commonly a skin biopsy) using detection methods that depend on the specific binding of anti-BVDV antibodies. Although these tests are widely used for the detection of PI animals they frequently fail to identify all infected animals (false negatives) resulting in the failure to remove all PI animals from the infected herd. Moreover, serological tests cannot differentiate between PIs and uninfected animals, or between acutely infected and vaccinated animals.
Identification and elimination of PI animals from an affected herd is the most cost effective measure to control and eradicate BVDV, underscoring the criticality of an inexpensive and convenient diagnostic test. It is an object of the invention to provide such a test and kit for performing the same.

SUMMARY OF THE INVENTION

In accordance with the present invention, methods and compositions for diagnosis of Bovine Viral Diarrhea Virus (BVDV) are disclosed. Specifically, a simple, convenient test for accurately diagnosing BVDV is provided. The instant method provides the means to differentiate cattle persistently infected with BVDV (PI) from control non-infected steers. Other markers are provided which enable the skilled person to identify 1) heifers carrying persistently infected fetuses; 2) heifers carrying transiently virally infected fetuses and 3) heifers carrying control, uninfected fetuses. Such differentiation may be accomplished by detecting altered expression levels of one or more markers shown in Tables 1-9, or the proteins or peptide fragments encoded thereby. Most preferably, the test can be easily conducted in the field by veterinarians or cattle producers.
In one aspect of the invention, BVDV surrogate markers are provided. A BVDV surrogate marker may be a nucleic acid or polypeptide or fragments thereof. Such markers are provided herein at Tables 1-9. Also provided in accordance with the invention are oligonucleotides, including probes and primers, that specifically hybridize with the nucleic acid sequences set forth in Tables 1-9. Antibodies immunologically specific for the BVDV marker polypeptides described herein are also within the scope of the invention.
In a further aspect of the invention, recombinant DNA molecules comprising the nucleic acid molecules set forth above, operably linked to a vector are provided. The invention also encompasses host cells comprising a vector encoding a BVDV specific marker of the invention.
In another aspect of the invention, methods for detecting a differentially expressed BVDV specific marker molecules in a biological sample are provided. Such molecules can be BVDV specific marker nucleic acids, such as mRNA, DNA, cDNA, or BVDV specific marker polypeptides or fragments thereof. Preferably the BVDV surrogate marker exhibits expression levels which differ at least 2 fold from normal, uninfected cattle. The BVDV markers of the invention may be up or down regulated relative to the levels observed in non-infected control cattle. Exemplary methods comprise detection of isolated biological molecules which hybridize to BVDV specific markers which are affixed to a solid support, or mRNA analysis, for example by RT-PCR. Immunological methods include for example contacting a sample with a detectably labeled antibody immunologically specific for a BVDV specific marker polypeptide and determining the presence of the polypeptide as a function of the amount of detectably labeled antibody bound by the sample relative to control cells. In a preferred embodiment, these assays may be used to detect differentially expressed proteins encoded by the nucleic acids set forth in Tables 1-9.
In a further aspect of the invention, kits for detection of BVDV infection or lack thereof are provided. An exemplary kit comprises a BVDV specific marker protein, polynucleotide or a gene chip comprising a plurality of such polynucleotides, or antibody, which are optionally linked to a detectable label. The kits may also include solid supports, pharmaceutically acceptable carriers and/or excipients, a suitable container, and instructions for use.
In yet another aspect of the invention, the differentially regulated BVDV markers described herein may be used in screening methods to identify new therapeutic agents for the treatment of viral infections, including BVDV infection.
Agents which affect the differential expression of nucleic acids or proteins associated with BVDV infection may prove efficacious for the treatment of BVDV.

BRIEF DESCRIPTION OF THE FIGURE

FIG. 1 is a schematic diagram showing some of the features of persistent and acute or transient BVDV infection.
FIG. 2 is a graph showing upregulation of interferon stimulated gene 15 (ISG15) in blood from persistently infected calves. ISGIS mRNA levels were determined using semi-quantitative (adjusted for GAPDH) Sybr green Real Time PCR. Blood from three persistently infected (PI) and three calves that had been vaccinated against BVDV (TI) are represented in the analysis. ISG15 means differ between PI and TI (P<0.05).
FIG. 3 is a graph showing select blood cell markers that are upregulated in bloods from persistently infected, when compared to non-infected steers using semi-quantitative Real Time PCR (GAPDH used as a control). The 28 kD (interferon induced 28 kD protein; CK771386), BST2 (bone marrow stromal cell surface antigen 2; CK846889), MX2 (myxovirus resistance 2; NM_—173941) and ISG15 (Interferon stimulated 15 kDa;NM_—174366) markers were all useful blood cell mRNA markers for distinguishing persistent viral infection (positive) when compared to control non-infected steers (negative). In this illustration, ISG15 and MX2 are preferred markers.
FIG. 4 is a heat plot illustrating three-Way ANOVA analysis of blood cell gene expression from mothers carrying control vs. TI vs. PI virally infected fetuses described in Table 9. This analysis represents a fold change of 1.5 fold or greater with P<0.01, Table 9 provides the actual P values for each comparison and a more complete description of each gene.

DETAILED DESCRIPTION OF THE INVENTION

Bovine viral diarrhea virus (BVDV) provides a challenge to cattle producers, because BVDV is a contagious and potentially lethal disease that is currently difficult and expensive to differentially diagnose. Current tests are performed on samples collected from young calves after birth. Thus, many of these infected calves have already shed virus and have infected other pregnant cows. Therefore reinfection of pregnant cows helps maintain the infectious cycle.
The complex host-viral interactions resulting from persistent infection are minimally understood, particularly in the bovine host. Thus, one purpose of the present research was to identify those genes and associated biological pathways which are activated or down-regulated in response to viral infection to facilitate a better understanding of the mechanism of virus action. Another objective of the research was to identify peripheral blood markers that will help distinguish pregnant cattle that are carrying persistently infected from those carrying transiently virally infected fetuses. Depending on the time of infection during gestation, noncytopathic (ncp) bovine viral diarrhea virus (BVDV) causes persistent infection (PI, <150 d) or transient infection (TI, >150 d.) in fetuses. TI fetuses develop immunity to the viral strain and clear the virus. PI fetuses do not recognize the virus as a foreign agent and once born continually shed the virus and infect other cattle. Detection and removal of pregnant cows or heifers carrying PI fetuses would greatly benefit the successful implementation of control programs. Provided herein is a simple and effective test for diagnosing BVDV, and identifying persistently infected (PI) animals.
Experimental evidence is provided which indicates that the pattern of gene expression in vaccinated or acutely infected and PI animals is different, and therefore the differential expression of genes can be used as a diagnostic marker for these types of BVDV infection. Genes that are differentially expressed in the cells of the blood or the skin of persistently infected animals (surrogate markers) are identified using gene chip analysis of mRNA of PI when compared to vaccinated or acutely infected animals. Antibodies produced against such surrogate markers can be used to develop a diagnostic test to detect PI animals, by analyzing the presence of the surrogate marker in an animal's blood or skin.
Thus, in accordance with the present invention, gene chip analysis has been performed on nucleic acids obtained from blood cells collected from bovines that are persistently infected with BVDV when compared to vaccinated control bovines.
In yet another aspect, the differentially regulated BVDV markers described herein may be used in screening methods to identify new therapeutic agents for the treatment of viral infections, particularly BVDV infections. For example, agents which down regulate the expression of genes which are upregulated in response to infection may have efficacy as antiviral agents.
I. Definitions
The following definitions are provided to facilitate an understanding of the present invention: The term “surrogate marker” or infection marker is a marker which is differentially expressed in animals infected with a pathological condition, such as a virus.
Specifically, a surrogate marker may be any gene expression product which is differentially expressed in persistently infected animals when compared to vaccinated or acutely infected animals, transiently infected and non-infected or non-vaccinated (normal) animals. A surrogate marker can be a polynucleotide, a protein, a peptide, or any gene expression product, but is preferably an mRNA or protein expression product. The surrogate markers described herein may also be useful for diagnosing invention with other RNA viruses which include for example, Influenza, HIV, Ebola virus, FeLv, FIP virus, Bluetongue virus, West Nile Virus, hepatitis C Virus and Epizootic Hemorrhagic Disease Virus. Thus, the term “surrogate marker” as used herein refers to those biological molecules which are differentially expressed in response to infection with any RNA virus.
A persistently infected calf is one that is infected in utero prior to 150 days of gestation, does not clear the virus and if it survives will continue to shed virus. A transiently infected calf is one that is infected in utero after 150 days of gestation, recovers and clears the virus. An acutely infected animal is one that is infected postnatally and recovers, clearing the virus, A control animal is one that was never infected with virus.
A “BVDV surrogate marker” refers to a marker which is differentially expressed in animals infected with BVDV. Specifically, a BVDV surrogate marker may be any gene expression product which is differentially expressed in any or all of acutely infected BVDV animals, persistently infected BVDV animals, vaccinated BVDV animals, and normal animals. A surrogate marker can be a polynucleotide, a protein or peptide, or any gene expression product, but is preferably an mRNA or protein expression product.
A “BVDV surrogate marker profile” is an expression pattern of surrogate BVDV markers which correlates specifically to acute BVDV infection, persistent BVDV infection, BVDV vaccinated cattle, or non-BVDV infected cattle.
A “sample” or “patient sample” or “biological sample” generally refers to a sample which may be tested for a particular molecule, preferably a surrogate BVDV marker, including one or more surrogate BVDV polynucleotide, polypeptide, or antibody. Samples may include but are not limited to blood or skin, serum, plasma, urine, saliva, and the like. Most preferably, the sample is a skin sample or a blood sample from cattle.
“Blood” includes but is not limited to whole blood, blood treated or mixed with anticoagulants, and any component of whole blood, including but not limited to serum, plasma, buffy coat, and purified peripheral blood mononuclear cells.
A “ruminant” is an even-toed, herbivorous, ungulate mammal (Order Artiodactyla) that chews cud (ruminate) and has a complex, usually four-chambered stomach containing micro-organisms that break down cellulose. Ruminants include but are not limited to cattle, sheep, antelope, deer, giraffes, elk, moose, caribou, yak and camelids (e.g., camel, llama, alpaca, vicuna and guanaco).
The term “cattle” as used herein includes any of numerous types of domestic quadrupeds held as property or raised for use, such as livestock, cows, bulls, bovine, steer, oxen, bison, and the like. The term “cattle” generally refers to multiple animals, but may also describe a single animal.
The term “ruminant nucleic acid” or “ruminant protein” refers to a nucleic acid or protein whose sequence is of ruminant origin. Preferably, a ruminant nucleic acid or ruminant protein is of bovine origin.
A “BVDV surrogate marker detector molecule” is a molecule which facilitates detecting or quantitating a BVDV surrogate marker. A BVDV surrogate marker detector molecule can be any molecule which facilitates detection of BVDV surrogate marker, including but not limited to a probe or primer which specifically hybridizes with a BVDV surrogate marker nucleic acid, or an antibody or fragment thereof which specifically binds to a BVDV surrogate marker polypeptide or peptide fragment.
The term “differential diagnosis” refers to a diagnosis which is able to differentiate between two or more different types of BVDV infection (for example, acute infection, persistent infection, or not infected.) This test also identifies previously vaccinated animals.
The phrase “consisting essentially of” when referring to a particular nucleotide or amino acid means a sequence having the properties of a given SEQ ID NO:.
For example, when used in reference to an amino acid sequence, the phrase includes the sequence per se and molecular modifications that would not affect the functional and unique characteristics of the sequence.
The term “nucleic acid molecule” describes a polymer of deoxyribonucleotides (DNA) or ribonucleotides (RNA). The nucleic acid molecule may be isolated from a natural source by cDNA cloning or subtractive hybridization or synthesized manually. The nucleic acid molecule may be synthesized manually by the triester synthetic method or by using an automated DNA synthesizer.
With regard to nucleic acids used in the invention, the term “isolated nucleic acid” is sometimes employed. This term, when applied to DNA, refers to a DNA molecule that is separated from sequences with which it is immediately contiguous (in the 5′ and 3′ directions) in the naturally occurring genome of the organism or virus from which it was derived. For example, the “isolated nucleic acid” may comprise a DNA molecule inserted into a vector, such as a plasmid or virus vector, or integrated into the genomic DNA of a prokaryote or eukaryote cells.
An “isolated nucleic acid molecule” may also comprise a eDNA molecule. An isolated nucleic acid molecule inserted into a vector is also sometimes referred to herein as a recombinant nucleic acid molecule.
The term “complementary” describes two nucleotides that can form multiple favorable interactions with one another. For example, adenine is complementary to thymine as they can form two hydrogen bonds. Similarly, guanine and cytosine are complementary since they can form three hydrogen bonds. Thus if a nucleic acid sequence contains the following sequence of bases, thymine, adenine, guanine and cytosine, a “complement” of this nucleic acid molecule would be a molecule containing adenine in the place of thymine, thymine in the place of adenine, cytosine in the place of guanine, and guanine in the place of cytosine. Because the complement can contain a nucleic acid sequence that forms optimal interactions with the parent nucleic acid molecule, such a complement can bind with high affinity to its parent molecule.
With respect to single stranded nucleic acids, particularly oligonucleotides, the term “specifically hybridizing” refers to the association between two single-stranded nucleotide molecules of sufficiently complementary sequence to permit such hybridization under pre-determined conditions generally used in the art (sometimes termed “substantially complementary”). In particular, the term refers to hybridization of an oligonucleotide with a substantially complementary sequence contained within a single-stranded DNA or RNA molecule of the invention, to the substantial exclusion of hybridization of the oligonucleotide with single- stranded nucleic acids of non-complementary sequence. Appropriate conditions enabling specific hybridization of single stranded nucleic acid molecules of varying complementarity are well known in the art.
For instance, one common formula for calculating the stringency conditions required to achieve hybridization between nucleic acid molecules of a specified sequence homology is set forth below (Sambrook et al. , Molecular Cloning, Cold Spring Harbor Laboratory (1989):
Tm 81.5° C +16.6 Log [Na+]+0.41 (% G+C)−0.63 (% formamide)−600/#bp in duplex.
As an illustration of the above formula, using [Na+]=[0.368] and 50% formamide, with GC content of 42% and an average probe size of 200 bases, the Tm is 57° C. The Tm of a DNA duplex decreases by 1-1.5° C. with every 1% decrease in homology. Thus, targets with greater than about 75% sequence identity would be observed using a hybridization temperature of 42° C.
The stringency of the hybridization and wash depend primarily on the salt concentration and temperature of the solutions. In general, to maximize the rate of annealing of the probe with its target, the hybridization is usually carried out at salt and temperature conditions that are 20-25° C. below the calculated Tm of the hybrid.
Wash conditions should be as stringent as possible for the degree of identity of the probe for the target. In general, wash conditions are selected to be approximately 12-20° C. below the Tm of the hybrid. In regards to the nucleic acids of the current invention, a moderate stringency hybridization is defined as hybridization in 6×SSC, 5× Denhardt's solution, 0.5% SDS and 100 pg/ml denatured salmon sperm DNA at 42° C., and washed in 2×SSC and 0.5% SDS at 55° C. for 15 minutes. A high stringency hybridization is defined as hybridization in 6×SSC, 5× Denhardt's solution, 0.5% SDS and 100 pg/ml denatured salmon sperm DNA at 42° C., and washed in 1×SSC and 0.5% SDS at 65° C. for 15 minutes. A very high stringency hybridization is defined as hybridization in 6×SSC, 5× Denhardt's solution, 0.5% SDS and 100 pg/ml denatured salmon sperm DNA at 42° C., and washed in 0.1×SSC and 0.5% SDS at 65° C. for 15 minutes.
The term “oligonucleotide” as used herein refers to primers and probes of the present invention, and is defined as a nucleic acid molecule comprised of two or more ribo-or deoxyribonucleotides, preferably more than three. The exact size of the oligonucleotide will depend on various factors and on the particular application and use of the oligonucleotide. Oligonucleotides, which include probes and primers, can be any length from 3 nucleotides to the full length of the nucleic acid molecule, and explicitly include every possible number of contiguous nucleic acids from 3 through the full length of the polynucleotide. Preferably, oligonucleotides, which include probes and/or primers are at least about 10 nucleotides in length, more preferably at least 15 nucleotides in length, more preferably at least about 20 nucleotides in length.
The term “probe” as used herein refers to an oligonucleotide, polynucleotide or nucleic acid, either RNA or DNA, whether occurring naturally as in a purified restriction enzyme digest or produced synthetically, which is capable of annealing with or specifically hybridizing to a nucleic acid with sequences complementary to the probe. A probe may be either single-stranded or double-stranded. The exact length of the probe will depend upon many factors, including temperature, source of probe and use of the method. For example, for diagnostic applications, depending on the complexity of the target sequence, the oligonucleotide probe typically contains 15-25 or more nucleotides, although it may contain fewer nucleotides. The probes herein are selected to be complementary to different strands of a particular target nucleic acid sequence.
This means that the probes must be sufficiently complementary so as to be able to “specifically hybridize” or anneal with their respective target strands under a set of pre-determined conditions. Therefore, the probe sequence need not reflect the exact complementary sequence of the target. For example, a non-complementary nucleotide fragment may be attached to the 5′ or 3′end of the probe, with the remainder of the probe sequence being complementary to the target strand. Alternatively, non-complementary bases or longer sequences can be interspersed into the probe, provided that the probe sequence has sufficient complementarity with the sequence of the target nucleic acid to anneal therewith specifically.
The term “primer” as used herein refers to an oligonucleotide, either RNA or DNA, either single- stranded or double-stranded, either derived from a biological system, generated by restriction enzyme digestion, or produced synthetically which, when placed in the proper environment, is able to functionally act as an initiator of template-dependent nucleic acid synthesis. When presented with an appropriate nucleic acid template, suitable nucleoside triphosphate precursors of nucleic acids, a polymerase enzyme, suitable cofactors and conditions such as a suitable temperature and pH, the primer may be extended at its 3 terminus by the addition of nucleotides by the action of a polymerase or similar activity to yield a primer extension product. The primer may vary in length depending on the particular conditions and requirement of the application. For example, in diagnostic applications, the oligonucleotide primer is typically 15-25 or more nucleotides in length. The primer must be of sufficient complementarity to the desired template to prime the synthesis of the desired extension product, that is, to be able anneal with the desired template strand in a manner sufficient to provide the 3 ′hydroxyl moiety of the primer in appropriate juxtaposition for use in the initiation of synthesis by a polymerase or similar enzyme. It is not required that the primer sequence represent an exact complement of the desired template.
For example, a non-complementary nucleotide sequence may be attached to the 5′end of an otherwise complementary primer. Alternatively, non-complementary bases may be interspersed within the oligonucleotide primer sequence, provided that the primer sequence has sufficient complementarity with the sequence of the desired template strand to functionally provide a template-primer complex for the synthesis of the extension product. Polymerase chain reaction (PCR) has been described in U.S. Pat. Nos. 4,683,195, 4,800,195, and 4,965,188, the entire disclosures of which are incorporated by reference herein.
The term “vector” relates to a single or double stranded circular nucleic acid molecule that can be transfected or transformed into cells and replicate independently or within the host cell genome. A circular double stranded nucleic acid molecule can be cut and thereby linearized upon treatment with restriction enzymes. An assortment of vectors, restriction enzymes, and the knowledge of the nucleotide sequences that are targeted by restriction enzymes are readily available to those skilled in the art. A vector of the invention includes any replicon, such as a plasmid, cosmid, bacmid, phage or virus, to which another genetic sequence or element (either DNA or RNA) may be attached so as to bring about the replication of the attached sequence or element. A nucleic acid molecule of the invention can be inserted into a vector by cutting the vector with restriction enzymes and ligating the two pieces together.
Many techniques are available to those skilled in the art to facilitate transformation, transfection, or transduction of the expression construct into a prokaryotic or eukaryotic organism. The terms “transformation”, “transfection”, and “transduction” refer to methods of inserting a nucleic acid and/or expression construct into a cell or host organism. These methods involve a variety of techniques, such as treating the cells with high concentrations of salt, an electric field, or detergent, to render the host cell outer membrane or wall permeable to nucleic acid molecules of interest, microinjection, PEG-fusion, and the like.
The term “promoter element” describes a nucleotide sequence that is incorporated into a vector that, once inside an appropriate cell, can facilitate transcription factor and/or polymerase binding and subsequent transcription of portions of the vector DNA into mRNA. In one embodiment, the promoter element of the present invention precedes the Send of the BVDV surrogate marker nucleic acid molecule such that the latter is transcribed into mRNA. Host cell machinery then translates mRNA into a polypeptide.
Those skilled in the art will recognize that a nucleic acid vector can contain nucleic acid elements other than the promoter element and the BVDV surrogate marker gene nucleic acid molecule. These other nucleic acid elements include, but are not limited to, origins of replication, ribosomal binding sites, nucleic acid sequences encoding drug resistance enzymes or amino acid metabolic enzymes, and nucleic acid sequences encoding secretion signals, periplasm or peroxisome localization signals, or signals useful for polypeptide purification.
An “expression operon” refers to a nucleic acid segment that may possess transcriptional and translational control sequences, such as promoters, enhancers, translational start signals (e.g., ATG or AUG codons), polyadenylation signals, terminators, and the like, and which facilitate the expression of a polypeptide coding sequence in a host cell or organism.
As used herein, the terms “reporter”, “reporter system”, “reporter gene”, or “reporter gene product” shall mean an operative genetic system in which a nucleic acid comprises a gene that encodes a product that when expressed produces a reporter signal that is a readily measurable, e.g., by biological assay, immunoassay, radio immunoassay, or by calorimetric, fluorogenic, chemiluminescent or other methods. The nucleic acid may be either RNA or DNA, linear or circular, single or double stranded, antisense or sense polarity, and is operatively linked to the necessary control elements for the expression of the reporter gene product. The required control elements will vary according to the nature of the reporter system and whether the reporter gene is in the form of DNA or RNA, but may include, but not be limited to, such elements as promoters, enhancers, translational control sequences, poly A addition signals, transcriptional termination signals and the like.
The introduced nucleic acid may or may not be integrated (covalently linked) into nucleic acid of the recipient cell or organism. In bacterial, yeast, plant and mammalian cells, for example, the introduced nucleic acid may be maintained as an episomal element or independent replicon such as a plasmid. Alternatively, the introduced nucleic acid may become integrated into the nucleic acid of the recipient cell or organism and be stably maintained in that cell or organism and further passed on or inherited to progeny cells or organisms of the recipient cell or organism. Finally, the introduced nucleic acid may exist in the recipient cell or host organism only transiently.
The term “selectable marker gene” refers to a gene that when expressed confers a selectable phenotype, such as antibiotic resistance, on a transformed cell.
The term “operably linked” means that the regulatory sequences necessary for expression of the coding sequence are placed in the DNA molecule in the appropriate positions relative to the coding sequence so as to effect expression of the coding sequence. This same definition is sometimes applied to the arrangement of transcription units and other transcription control elements (e.g., enhancers) in an expression vector.
The term “tag”, “tag sequence”, or “protein tag” refers to a chemical moiety, either a nucleotide, oligonucleotide, polynucleotide or an amino acid, peptide or protein or other chemical, that when added to another sequence, provides additional utility or confers useful properties, particularly in the detection or isolation, of that sequence. Thus, for example, a homopolymer nucleic acid sequence or a nucleic acid sequence complementary to a capture oligonucleotide may be added to a primer or probe sequence to facilitate the subsequent isolation of an extension product or hybridized product. In the case of protein tags, histidine residues (e. g., 4 to 8 consecutive histidine residues) may be added to either the amino-or carboxy-terminus of a protein to facilitate protein isolation by chelating metal chromatography. Alternatively, amino acid sequences, peptides, proteins or fusion partners representing epitopes or binding determinants reactive with specific antibody molecules or other molecules (e. g., flag epitope, c-mye epitope, transmembrane epitope of the influenza A virus hemaglutinin protein, protein A, cellulose binding domain, calmodulin binding protein, maltose binding protein, chitin binding domain, glutathione S-transferase, and the like) may be added to proteins to facilitate protein isolation by procedures such as affinity or immunoaffinity chromatography.
Chemical tag moieties include such molecules as biotin, which may be added to either nucleic acids or proteins and facilitates isolation or detection by interaction with avidin reagents, and the like. Numerous other tag moieties are known to, and can be envisioned by the trained artisan, and are contemplated to be within the scope of this definition.
A “specific binding pair” comprises a specific binding member (sbm) and a binding partner (bp) which have a particular specificity for each other and which in normal conditions bind to each other in preference to other molecules. Examples of specific binding pairs are antigens and antibodies, ligands and receptors and complementary nucleotide sequences. The skilled person is aware of many other examples. Further, the term “specific binding pair” is also applicable where either or both of the specific binding member and the binding partner comprise a part of a large molecule. In embodiments in which the specific binding pair comprises nucleic acid sequences, they will be of a length to hybridize to each other under conditions of the assay, preferably greater than 10 nucleotides long, more preferably greater than 15 or 20 nucleotides long.
An “antibody” or “antibody molecule” is any immunoglobulin, including antibodies and fragments thereof that binds to a specific antigen. The term includes polyclonal, monoclonal, chimeric, and bispecific antibodies. Exemplary antibody fragments, capable of binding an antigen or other binding partner, are Fab fragment consisting of the VL, VH, Cl and CH1 domains; the Fd fragment consisting of the VH and CH1 domains; the Fv fragment consisting of the VL and VH domains of a single arm of an antibody; the dAb fragment which consists of a VH domain; isolated CDR regions and F (ab′) 2 fragments, a bivalent fragment including two Fab fragments linked by a disulphide bridge at the hinge region. Single chain Fv fragments are also included.
With respect to antibodies, the term “immunologically specific” refers to antibodies that bind to one or more epitopes of a protein or compound of interest, but which do not substantially recognize and bind other molecules in a sample containing a mixed population of antigenic biological molecules. Exemplary antibodies bind to a protein or peptide fragment encoded by a nucleotide sequence set forth in Tables 1-9.
A “detection reagent” or a “marker detection reagent” is any substance which has binding affinity for a BVDV specific molecule, and includes but is not limited to nucleic acid molecules with sufficient affinity to hybridize to the BVDV specific marker, probes, primers, antibodies, fragments thereof and the like. The “detection reagent” or “marker detection reagent” may optionally be detectably labeled.
The term “detectable label” is used herein to refer to any substance whose detection or measurement, either directly or indirectly, by physical or chemical means, is indicative of the presence of a target bioentity in a test sample. Representative examples of useful detectable labels, include, but are not limited to the following: molecules or ions directly or indirectly detectable based on light absorbance, fluorescence, reflectance, light scatter, phosphorescence, or luminescence properties; molecules or ions detectable by their radioactive properties; molecules or ions detectable by their nuclear magnetic resonance or paramagnetic properties. Included among the group of molecules indirectly detectable based on light absorbance or fluorescence, for example, are various enzymes which cause appropriate substrates to convert, e. g., from non-light absorbing to light absorbing molecules, or from non-fluorescent to fluorescent molecules.
II. Surrogate BVDV Nucleic Acid Molecules, Probes, and Primers and Methods of Preparing the Same
Encompassed by the invention are surrogate BVDV nucleic acid molecules, nucleic acid molecules which encode isolated, enriched, or purified surrogate BVDV proteins or peptides, including allelic variations, analogues, fragments, derivatives, mutants, and modifications of the same.
Surrogate BVDV nucleic acid molecules, and nucleic acid sequences encoding surrogate BVDV proteins may be isolated from appropriate biological sources using methods known in the art. In a preferred embodiment, a cDNA clone is isolated from a cDNA expression library of bovine origin. Preferably, the sample is isolated from a bovine which has been vaccinated for, or has acute, or persistent BVDV infection, Surrogate BVDV marker polynucleotides can be any one of, or any combination of the markers shown in Tables 1-9, and further may include variants which are at least about 75%, or 80% or 85% or 90% or 95%, and often, more than 90%, or more than 95% homologous to the markers shown in Tables 1-9, over the full length sequence. Surrogate BVDV marker polynucleotides also may be 60% or 65% or 70% or 75% or 80% or 85% or 90% or 95% or 97% or 98% or 99% or greater than 99% homologous to the markers shown in Tables 1-9, over the full length sequence. All homology may be computed by algorithms known in the art, such as BLAST, described in Altschul et al. (1990), J. Mol. Biol. 215: 403-10, or the Smith-Waterman homology search algorithm as implemented in MPSRCH program (Oxford Molecular). Someone of ordinary skill in the art would readily be able to determine the ideal gap open penalty and gap extension penalty for a particular nucleic acid sequence.
Exemplary search parameters for use with the MPSRCH program in order to identify sequences of a desired sequence identity are as follows: gap open penalty:-16; and gap extension penalty:-4.
Degenerate variants are also encompassed by the instant invention. The degeneracy of the genetic code permits substitution of certain codons by other codons, which specify the same amino acid and hence would give rise to the same protein. The nucleic acid sequence can vary substantially since, with the exception of methionine and tryptophan, the known amino acids can be coded for by more than one codon. Thus, portions or all of the markers could be synthesized to give a nucleic acid sequence significantly different from that shown in Tables 1-9. The encoded amino acid sequence thereof would, however, be preserved.
In addition, the nucleic acid sequence may comprise a nucleotide sequence which results from the addition, deletion or substitution of at least one nucleotide to the 5′-end and/or the 3′-end of one or more of the markers shown in Tables 1-9, or a derivative thereof. Any nucleotide or polynucleotide may be used in this regard, provided that its addition, deletion or substitution does not alter the amino acid sequence which is encoded by the nucleotide sequence, or it still shares a region of homology with one or more of the markers shown in Tables 1-9. For example, the present invention is intended to include any nucleic acid sequence resulting from the addition of ATG as an initiation codon at the 5′-end of the surrogate BVDV marker nucleic acid sequence or its functional derivative, or from the addition of TTA, TAG or TGA as a termination codon at the 3′-end of the inventive nucleotide sequence or its derivative. Moreover, the nucleic acid molecule of the present invention may, as necessary, have restriction endonuclease recognition sites added to its 5′-end and/or 3′-end.
Such functional alterations of a given nucleic acid sequence afford an opportunity to promote secretion and/or processing of heterologous proteins encoded by foreign nucleic acid sequences fused thereto. All variations of the nucleotide sequence of the markers shown in Tables 1-9 and fragments thereof permitted by the genetic code are, therefore, included in this invention.
In an alternative embodiment, utilizing the sequence information provided by the eDNA sequence, genomic clones encoding a surrogate BVDV marker gene may be isolated.
Alternatively, eDNA or genomic clones having homology with the markers shown in Tables 1-9 may be isolated from other species, such as mouse or human, using oligonucleotide probes corresponding to predetermined sequences within surrogate BVDV marker gene.
III. Surrogate BVDV Proteins (Antigens) and Methods of Making the Same
Encompassed by the invention are isolated, purified, or enriched surrogate BVDV polypeptides, including allelic variations, analogues, fragments, derivatives, mutants, and modifications of the same which are differentially expressed in BVDV animals. Preferably, surrogate BVDV marker polypeptides include polypeptides encoded by one or more of the sequences shown in Tables 1-9. Surrogate BVDV marker function is defined above, and includes increased or decreased expression in response to BVDV infection, cross-reactivity with an antibody reactive with the polypeptides encoded by one or more of the sequences shown in Tables 1-9 or sharing an epitope with the same (as determined for example by immunological cross-reactivity between the two polypeptides). Surrogate BVDV marker polypeptides or proteins can be encoded by one or more of the sequences shown in Tables 1-9, and further may include variants which are at least about 75%, or 80% or 85% or 90% or 95%, and often, more than 90%, or more than 95% homologous to the same over the full length sequence.
Surrogate BVDV marker polypeptides also may be 60% or 65% or 70% or 75% or 80% or 85% or 90% or 95% or 97% or 98% or 99% or greater than 99% homologous to polypeptides encoded by one or more of the sequences shown in Tables 1-9 over the full length sequence. All homology may be computed by algorithms known in the art, such as BLAST, described in Altschul et al. (1990), J. Mol. Biol. 215: 403-10, or the Smith-Waterman homology search algorithm as implemented in MPSRCH program (Oxford Molecular). Someone of ordinary skill in the art would readily be able to determine the ideal gap open penalty and gap extension penalty for a particular protein sequence. Exemplary search parameters for use with the MPSRCH program in order to identify sequences of a desired sequence identity are as follows: gap open penalty:-12 ; and gap extension penalty:-2.
A full-length or truncated surrogate BVDV protein of the present invention may be prepared in a variety of ways, according to known methods. The protein may be purified from appropriate sources, e.g., transformed bacterial or animal cultured cells or tissues, by immunoaffinity purification. Additionally, the surrogate BVDV protein may be produced using in vitro expression methods known in the art. For example, a cDNA or gene may be cloned into an appropriate in vitro transcription vector, such as pSP64 or pSP65 for in vitro transcription, followed by cell-free translation in a suitable cell-free translation system, such as wheat germ or rabbit reticulocyte lysates. In vitro transcription and translation systems are commercially available, e. g., from Promega Corp., Madison, Wis. or Invitrogen Corp., Carlsbad, Calif.
The surrogate BVDV proteins produced by gene expression in a recombinant prokaryotic or eukaryotic system may be purified according to methods known in the art. In a preferred embodiment, a commercially available expression/secretion system can be used, whereby the recombinant protein is expressed and thereafter secreted from the host cell, to be easily purified from the surrounding medium. If expression/secretion vectors are not used, an alternative approach involves purifying the recombinant protein by affinity separation, such as by immunological interaction with antibodies that bind specifically to the recombinant protein or nickel columns for isolation of recombinant proteins tagged with 6-8 histidine residues at their N-terminus or C-terminus.
Alternative tags may comprise the FLAG epitope or the hemagglutinin epitope. Such methods are commonly used by skilled practitioners.
IV. Anti-Surrogate BVDV Protein Antibodies and Methods of Making the Same
The present invention also provides methods of making and using antibodies capable of immunospecifically binding to surrogate BVDV proteins. Polyclonal antibodies directed toward surrogate BVDV proteins may be prepared according to standard methods. In a preferred embodiment, monoclonal antibodies are prepared, which react immunospecifically with the various epitopes on the surface of the surrogate BVDV protein. Monoclonal antibodies may be prepared according to general methods of Kohler and Milstein, following standard protocols.
Purified BVDV antigens, or fragments thereof, may be used to produce polyclonal or monoclonal antibodies which also may serve as sensitive detection reagents for the various types of BVDV infection (acute, PI, vaccination reaction, and not infected). Recombinant techniques enable expression of fusion proteins containing part or all of BVDV. The surrogate BVDV protein itself, or surface proteins or antigens from the surrogate BVDV protein may be used to advantage to generate an array of monoclonal antibodies specific for various epitopes of the surrogate BVDV protein, thereby providing even greater sensitivity for detection of the surrogate BVDV protein (and thus BVDV infection) in samples.
Polyclonal or monoclonal antibodies that immunospecifically interact with BVDV antigens can be utilized for identifying and diagnosing BVDV. For example, antibodies may be utilized for affinity separation of proteins with which they immunospecifically interact. Antibodies may also be used to immunuoprecipitate proteins from a sample containing a mixture of proteins and other biological molecules.
Other uses of anti-surrogate BVDV protein antibodies are described below.
V. Methods of Using Surrogate BVDV Polynucleotides, Polypeptides, and Antibodies for Screening and Diagnostic Assays
Surrogate BVDV nucleic acids may be used for a variety of purposes in accordance with the present invention. Surrogate BVDV nucleic acids (DNA, RNA, fragments thereof, etc.), or protein-encoding DNA, RNA, or fragments thereof may be used as probes to detect the presence of surrogate BVDV nucleic acids or protein in a sample. Methods in which surrogate BVDV nucleic acids and protein-encoding nucleic acids may be utilized as probes for such assays include, but are not limited to, (1) in situ hybridization; (2) Southern hybridization (3) northern hybridization; (4) gene chip analysis and (5) assorted amplification reactions such as polymerase chain reactions (PCR).
Exemplary surrogate BVDV nucleic acids and nucleic acids encoding exemplary surrogate BVDV proteins or peptides are described in Tables 1-9.
The surrogate BVDV nucleic acids of the invention may also be utilized as probes to identify related surrogate BVDV variants. As is well known in the art, hybridization stringencies may be adjusted to allow hybridization of nucleic acid probes with complementary sequences of varying degrees of homology. Thus, BVDV surrogate marker nucleic acids may be used to advantage to identify and characterize other genes of varying degrees of relation to BVDV surrogate markers, thereby enabling further characterization of BVDV surrogate markers. Additionally, they may be used to identify genes encoding proteins that interact with BVDV surrogate markers (e. g., by the “interaction trap” technique-see for example Current Protocols in Molecular Biology, ed. Ausubel, F. M., et al., John Wiley & Sons, NY, 1997), which should further accelerate identification of the molecular components involved in BVDV. Finally, they may be used in assay methods to detect BVDV.
Polyclonal or monoclonal antibodies immunologically specific for proteins encoded by BVDV surrogate markers or peptide fragments thereof may be used in a variety of assays designed to detect and quantitate the protein, as well as to detect ruminant BVDV by detecting upregulation of BVDV surrogate markers. Such assays include, but are not limited to: (1) flow cytometric analysis; (2) immunochemical localization of BVDV specific markers in a body cell, tissue, or fluid; and (3) immunoblot analysis (e. g., dot blot, Western blot) (4) ELISA; (5) radioimmunoassay of extracts from various cells.
Additionally, as described above, anti-surrogate BVDV marker protein can be used for purification of surrogate BVDV markers (e. g., affinity column purification, immunoprecipitation).
Further, assays for detecting and quantitating surrogate BVDV markers, or to detect ruminant BVDV by detecting upregulation of BVDV specific markers may be conducted on any type of biological sample where upregulation of these molecules is observed, including but not limited to body fluids (including blood, serum, plasma, milk, or saliva), any type of cell (such as skin cells, or blood cells, or endothelial cells), or body tissue.
From the foregoing discussion, it can be seen that surrogate BVDV marker nucleic acids, surrogate BVDV marker expressing vectors, surrogate BVDV marker proteins and anti-surrogate BVDV marker antibodies of the invention can be used to detect surrogate BVDV marker expression in body tissue, cells, or fluid, and alter BVDV specific marker protein expression for purposes of assessing the genetic and protein interactions involved in BVDV and infection.
In most embodiments for screening for surrogate BVDV mRNA, surrogate BVDV nucleic acid in the sample will initially be amplified, e. g. using PCR, to increase the amount of the template as compared to other sequences present in the sample. This allows the target sequences to be detected with a high degree of sensitivity if they are present in the sample.
Thus any of the aforementioned techniques may be used as a diagnostic tool for detecting surrogate BVDV markers.
Further, these techniques could be used to diagnose infectious diseases in humans, by detection of a surrogate marker (rather than a viral antigen). For example, differential gene expression could be measured in HIV, Ebola, Hepatitis, and Herpes viral infections, etc. These tests are advantageous in that they are directed to detection of a theoretically harmless surrogate marker, rather than the infectious agent itself.
Such techniques could also be used to diagnose infectious diseases in companion animals by detection of a surrogate marker (rather than a viral antigen). An example of a potential application would be the diagnosis of feline infectious peritonitis of cats and latent viral infections caused by herpes viruses for which current diagnostic tests (based on isolation and characterization of the virus) have a marginal reliability. In addition, this technology could also be used for the diagnosis of cancer through the identification of surrogate cancer markers.
The instant inventive method improves upon the accuracy of current BVDV tests. A combination test, which measures both BVDV itself, and also one or more BVDV surrogate marker, to differentially diagnose BVDV infection provides superior diagnostic results in the field.
VI. Assays for Differentially Diagnosing BVDV Using Specific Surrogate Markers
In accordance with the present invention, it has been discovered that Bovine Viral Diarrhea Virus (BVDV) is correlated with increased expression levels of certain markers, including but not limited to mRNAs and proteins.
Thus, these molecules may be utilized in conventional assays to differentially diagnose BVDV. The detection of one or more of these differentially expressed BVDV surrogate molecules in a sample is indicative of BVDV. Similarly, specific patterns of expression allow detection of acute versus persistent infection. Alternatively, the absence of these molecules in a sample indicates that a ruminant is not infected with BVDV.
In an exemplary method, a blood sample is obtained from a bovine suspected of having an acute or persistent BVDV infection. Optionally, the blood may be centrifuged through a Hypaque gradient to obtain the buffy coat. The blood or buffy coat preparation is diluted and subjected to polymerase chain reaction conditions suitable for amplification of the BVDV surrogate marker encoding mRNA.
In certain applications, it may be necessary to include an agent, which lyses cells prior to performing the PCR.
Such agents are well known to the skilled artisan. The reaction products are then analyzed, e.g., via gel electrophoresis. An increase in BVDV surrogate marker mRNA levels relative to levels obtained from a non-infected bovine is indicative of BVDV in the animal being tested. Alternatively, an increase in BVDV surrogate markers in Al animals relative to Pt animals, or in PI animals, relative to Al animals, can differentially diagnose acute infection, or persistent infection.
In an alternative method, a skin tissue sample is obtained from the bovine suspected of having acute or persistent BVDV infection. The cells are then lysed and PCR performed. As above, an increase in BVDV surrogate marker mRNA expression levels relative to those observed in a non-BVDV infected animal being indicative of BVDV in the test animal.
It is also possible to detect BVDV using immunoassays. In an exemplary method, blood is obtained from a bovine suspected of being infected with BVDV. As above, the blood may optionally be centrifuged through a Hypaque gradient to obtain a buffy coat. The blood or buffy coat sample is diluted and at least one antibody immunologically specific for BVDV surrogate markers is added to the sample. In a preferred embodiment, the antibody is operably linked to a detectable label. Also as described above, the cells may optionally be lysed prior to contacting the sample with the antibodies immunologically specific for BVDV surrogate markers.
Increased production of BVDV surrogate markers is assessed as a fuaction of an increase in the detectable label relative to that obtained in parallel assays using blood from non-BVDV infected cow. In yet another embodiment, the blood or buffy coat preparation is serially diluted and aliquots added to a solid support.
Suitable solid supports include multi-well culture dishes, blots, filter paper, and cartridges. The solid support is then contacted with the detectably labeled antibody and the amount of BVDV surrogate marker protein (e.g., a protein or peptide encoded by a nucleic acid of Tables 1-9) in the animal suspected of being infected with BVDV is compared with the amount obtained from a non-AI or PI animal as a function of detectably labeled antibody binding. An alteration in the BVDV surrogate marker protein level in the test animal relative to the non-AI or PI infected control animal is indicative of acute or persistent BVDV.
In another embodiment, a first antibody which binds to a first epitope on a target protein is placed in the well of a cartridge. Whole blood, blood collected in the presence of anticoagulants (e.g., sodium citrate, heparin), plasma, or serum is placed into the well of the cartridge. The target protein, if present in the sample, is bound by the first antibody, and then migrates laterally by a wicking action, through a filter which has been sprayed with second antibody. The second antibody has affinity for a second epitope on the target protein, or alternatively for the first antibody. The second antibody is optionally labeled with a detectable label (e. g. radiolabel, gold, biotin, enzyme, etc.) The second antibody localizes the antigen, and results in the appearance of a line on the filter. The first and second antibodies may be generated against the full length target protein, or against the N-terminal or C-terminal halves of the target protein, so that they recognize different epitopes of the target protein.
The foregoing immunoassay methods may also be applied to any type of sample, including a urine sample.
VII. Kits and Articles of Manufacture
Any of the aforementioned products or methods can be incorporated into a kit which may contain a BVDV specific polynucleotide, an oligonucleotide, a polypeptide, a peptide, a solid support (e.g., filters, cartridges, gene chips) an antibody, a label, marker, or reporter, a pharmaceutically acceptable carrier, a physiologically acceptable carrier, instructions for use, negative and positive control samples, a container, a vessel for administration, an assay substrate, or any combination thereof.
The following materials and methods are provided to facilitate the practice of the invention. The Examples illustrate certain embodiments of the invention. They are not intended to limit its scope in any way.

EXAMPLE 1

Bovine viral diarrhea virus (BVDV) infections are responsible for important economic losses due to reproductive wastage, and respiratory and digestive disease in cattle. Infection of the early developing fetus frequently results in persistent infection (Pt). PI animals are the main source of new infection in herd mates. The complex host-viral interactions resulting from persistent infection are minimally understood, particularly in the bovine host. We hypothesized that gene expression would differ in bloods collected from PI when compared to non-infected steers. In preliminary studies, bloods were collected from three PI or three control steers and were processed to yield total cellular RNA. Labeled RNA was used to screen six independent bovine Affymetrix DNA chips, and analyzed for fold-changes at the University of Colorado Health Sciences Center Microarray Facility. The top 100 up-regulated genes belonged to MHC class I (45-fold), antiviral (32-100 fold), transcription factor (8-12 fold), interferon stimulated genes (5-28 fold), bone remodeling (4-9 fold), and chemokine (2-4) families. The top 100 down-regulated genes belonged to adhesion (5-10 fold), T-cell receptor (5-10 fold), extracellular matrix (3-5 fold), growth factor (2-3 fold), and transcription factor (2-3 fold) families. We conclude from these findings that persistent infection with BVDV results in antiviral responses in blood cells which includes induction of type 1 interferon-induced genes, chemokine-mediated immune responses and bone remodeling with a concomitant suppression of extracellular remodeling, adhesion and T-cell-mediated responses. Thus, in accordance with the present invention, single and/or multiplexing diagnostics for identifying cattle that are persistently infected with BVDV are provided.
BVDV is divided into two biotypes: cytopathic (cp) and non-cytopathic (nep). There are at least two recognized genotypes based on the sequence of the 5′ untranslated region, type I and type II, and additional sub-genotypes. Within each genotype, there are several strains that cause different degrees of clinical signs. The pathogenesis of BVDV infection has features that are unique to this virus and that vary with the virulence of the viral strain and age of the animal at the time of infection.
Particularly interesting are the outcomes of infection of the fetus. Infection of the fetus during the first 150 days of gestation, when the immune system has not yet developed, can lead to the generation of PI calves (FIG. 1). Some of these PI calves die soon after birth, but others live for relatively long periods of time without showing any clinical signs. PI animals cannot eliminate the infecting BVDV from their system and continuously release high amounts of virus in their bodily secretions. This makes them a continuous source of infection within the herd and potentially to other herds. When the infection occurs after 150 days of gestation (post-development of the immune system) or after birth, the infection is referred to as acute and these animals, which clear the virus, are frequently called transiently infected (TI). The clinical manifestations of acute infections with BVDV range from sub-clinical, or unapparent infections, to embryonic death, abortions, stillbirths, and malformed or slow-growing calves. Although recent studies indicate that transient infection of the fetus may cause long-term detrimental effects in the development of the calf, the basis for these effects is not clearly understood.
Acute infection with the nep biotype results in inhibition of double-stranded RNA-induced apoptosis and type 1 interferon, both indicated as plausible contributors to the establishment of persistent infection. However, in vitro and in vivo infections with the cp biotype induce apoptosis and are associated with increased type I interferon production.
The role of PI animals in the perpetuation of BVDV infections cannot be overemphasized. The presence of a single PI calf in a herd can cause severe losses within that herd and any herd with which the PI calf makes contact. The large percentage of seropositive cattle due to vaccination in the USA diminishes the value of serology as a monitoring test. In addition, PI animals have absent, extremely low or fluctuating titers against the strain that causes the persistent infection, potentially leading to misdiagnosis, particularly when serology is used as the only test. Current diagnostic tests based on the detection of viral antigen or viral RNA are effective tools for the identification of postnatal detection of PI animals. However, since PI animals shed high amounts of virus, early elimination of PI fetuses should greatly contribute to disrupting the infectious viral cycle.
In other preliminary studies, we demonstrated that calves persistently infected with BVDV present a differential pattern of gene expression in the blood when compared to vaccinated or acutely infected age-matched herd mates. We investigated the gene expression profiles in the whole blood of one year old PI and non-infected calves that were naturally infected with BVDV using DNA microarray approaches.
Blood samples were collected from three BVDV PI and three vaccinated, non-infected control calves in sodium citrate tubes and placed on ice. RNA was isolated using the QIAamp RNA Blood Mini Kit following the manufacturer's instructions (Qiagen). Red blood cells were selectively lysed, and white cells were collected by centrifugation. White cells were then lysed using highly denaturing conditions, which immediately inactivate RNases. After homogenization using the QIAshredder spin column, the sample was applied to the QIAamp spin column. Total RNA binds to the QIAamp membrane and contaminants were washed away, leaving pure RNA which was eluted in 30-100 μl RNase-free water.

The total RNA was isolated and used for transcriptional profiling by screening the Affymetrix bovine DNA chip. Biotinylated cRNA (15 μg), generated from each RNA sample (n=6 total), was hybridized to the bovine Affymetrix GeneChip (features of which are shown below) Array (n=6 total). Data were analyzed using Affymetrix Microarray Suite Software version 5.0 for absolute and pair-wise comparison analyses. Normalized expression values for the mean and standard deviation of three replicate average difference scores were calculated for each gene. Comparisons were performed using the Student's t test (P<0.05 was considered significant). The raw data were interpreted using GeneSpring (version 5.0, Silicon Genetics, Redwood, Calif.) and GeneSifter software (vizX Labs, LLC, Seattle, Wash.)



Critical Specifications

	Bos taurus (Bovine) probe sets	24,072
	Bos taurus (Bovine) transcripts	approximately 23,000
	UniGene clusters	approximately 19,000

Unique probe sets to single species:

	Number of arrays in set	one
	Array format	100
	Feature size	11 μm
	Oligonucleotide probe length	25-mer
	Probe pairs/sequence	11
	Hybridization controls:	bioB, bioC, bioD, from
		E. coli and cre from
		P1 B. subtilis
	Poly-A controls:	dap, lys, phe, thr, trp from
		B. subtilis
	Housekeeping/Control genes:	actin, GAPDH, eflα,
		5.8S rRNA, 12S rRNA,
		18S rRNA, cyclophilin B,
		glutathione S-transferase,
		lactophorin, translation
		initiation factor elF-4E
	Detection sensitivity	1:100,000¹

	¹As measured by detection in comparative analysis between a complex target containing spiked control transcriptions and a complex target with no spikes

Results

Two hundred genes were up-regulated in blood from PI when compared to vaccinated control calves. Known attributes of the top 100 up-regulated genes and fold changes are listed below.



45	fold	MHC Class I Molecules
10-32	fold	Antiviral genes
8-12	fold	Signal Transduction Molecules
5-28	fold	Type	1 Interferon-Induced Genes (FIG. 2)
4-9	fold	Bone Remodeling Genes
3-6	fold	Cytoskeletal Remodeling Genes
2-4	fold	Chemokine Ligands and Receptors

One hundred genes were down-regulated in blood from PI when compared to control calves. Known attributes of the top 100 down-regulated genes and fold changes are listed below.

5-10 fold Adhesion Molecules

5-10 fold T Cell Receptors

3-5 fold Extracellular Matrix

2-3 fold Growth Factors

2-3 fold Chemokine Ligands

2-3 fold Transcription Factors

See FIG. 2.
Following more extensive and stringent analysis of microarray data described above, the following up-regulated (Table 1) and down-regulated (Table 2) genes were identified as preferred bovine blood markers for BVDV persistent infection (n =2 steers) when compared with controls (n=3 steers). MX2, 2′-5′ oligoadenylate synthetase (OAS) and Interferon-Stimulated Protein, 15 kDa serve as examples of good markers for cattle with a BVDV PI infection when compared to non-infected controls. See FIG. 3.
As can be seen by the data presented herein, persistent infection with BVDV causes up-regulation and down-regulation of genes in blood cells. Persistent infection with BVDV results in antiviral responses in blood cells. The results show induction of interferon-induced genes, chemokine-mediated immune responses and bone remodeling genes. Suppression of extracellular remodeling, adhesion and T-cell-mediated responses is also observed. One gene, called interferon stimulated gene 15 or ISG15 was confirmed to be up-regulated in bloods from PI when compared to control vaccinated steers using blood cell mRNA and Real Time PCR approaches (FIGS. 2 and 3).

EXAMPLE 2

We hypothesized that gene expression in white blood cells would differ in pregnant heifers carrying PI, TI or uninfected (control) fetuses. Non-vaccinated heifers were purchased, confirmed to be seronegative for BVDV and were placed on growing rations until they were old enough to be artificially inseminated and confirmed to be pregnant. Heifers were infected with noncytopathic BVDV2 on day 75 to generate PI fetuses, on day 175 to generate TI fetuses, or were not infected (n=6 heifers per treatment). Bloods were collected on days 0, 37, 75, 78, 82, 90, 120, 160, 175, 178, 182 and 190 of gestation for RNA, serology and virology. Fetuses were delivered on d. 190 by C-section and necropsied. Maternal blood mRNA on day 190 of gestation was screened using the bovine Affymetrix gene chips.

BVDV infection in heifers and fetuses was confirmed using ELISA and qRT-PCR. Infected pregnant heifers were seropositive for BVDV by days 15-45 post infection. PI fetuses weighed less and were smaller with maldeveloped bone and muscle tissue (P<0.05) when compared to TI or UI fetuses. Screening of 24,000 transcripts on the bovine Affymetrix DNA chip using mRNA from blood cells of heifers on day 190 of pregnancy revealed 67 differentially expressed genes (1.5 fold or greater; P<0.05) based on infection status of the fetus: 32 genes in PI vs. TI, 26 genes in PI vs. control and 47 genes in TI vs. control. These genes were classified based on ontology analysis in primary categories of immune response, antigen presentation, inflammatory response, chemotaxis, protein folding and modification, transport, and defense response to bacteria. Specific genes that are differentially expressed are described in Tables 3-9.

TABLE 9


Analysis of blood gene expression using a three-way ANOVA in heifers carrying control vs. TI vs. PI fetuses. Analysis represents the top
24 genes that were differentially expressed in at least one of the treatment groups. The value in the ANOVA column represents the P value
when determining if one of the three means differs. Please refer to the heat plot in FIG. 4 for an illustration of these data.

	Control	TI	PI	Control	PI	TI	Gene
ANOVA	Mean	Mean	Mean	SEM	1	SEM 2	SEM 3	Identifier	Gene Title

0.006032	8.00309	10.9193	8.96783	0.188264	0.138741	0.660686	CK960499	2′-5′-oligoadenylate synthetase 1
								(OAS1)
0.003154	10.115	11.9521	10.7336	0.256113	0.176554	0.231053	NM_174366	interferon-stimulated protein. 15 kDa
0.003028	6.90223	8.43096	7.26529	0.101244	0.219103	0.222812	CK955157	XP_513514.1 similar to Interferon-induced
								protein 44 (Antigen p44)
0.003101	8.16371	9.68817	8.57334	0.191589	0.15614	0.212549	CB460780	XP_513514.1 similar to Interferon-induced
								protein 44 (Antigen p44)
0.003419	6.74951	8.13573	7.04487	0.104431	0.170809	0.23341	CK777675	XP_513514.1 similar to Interferon-induced
								protein 44 (Antigen p44)
0.001684	7.22418	8.76654	7.80757	0.137263	0.093874	0.232921	CB433489	pir: S48218 (H. sapiens) S48218 microtubular
								aggregate protein - hu
0.008299	8.21365	9.31672	8.57504	0.110353	0.233574	0.116391	CB432365	XP_520524.1 similar to DEAD/H
								(Asp-Glu-Ala-Asp/His) box polype
0.00315	8.16901	9.22019	9.12652	0.048718	0.109524	0.209197	CB445920	Transcribed sequences
0.002321	9.87333	9.15127	9.88773	0.12978	0.095443	0.033274	CK953227	XP_518477.1 similar to beta-tubulin
								cofactor C [Pan troglodytes]
0.009597	5.57083	5.66441	6.21629	0.161879	0.077099	0.026107	CK971667	XP_524698.1 similar to TAL1 (SCL)
								interrupting locus; SCL interrup
0.000202	8.26679	7.64432	8.09498	0.036558	0.065628	0.028333	BP103941	XP_521146.1 similar to ATRX
								[Pan troglodytes]
0.005323	6.91205	6.14205	7.06362	0.125015	0.061868	0.179441	CB534327	Component 3
0.003199	5.25886	5.54151	5.89927	0.099747	0.072327	0.051183	CB443429	NP_001804.1 centromere protein E, 312 kDa
								[Homo sapiens]
0.00661	7.76552	7.11499	8.06201	0.028002	0.114012	0.201076	CB460964	ATP-binding cassette transporter
								subfamily B, member 1 (ABCB1)
0.006969	5.88815	6.50156	6.25403	0.108627	0.090517	0.04993	CK770915	XP_218427.2 similar to poliovirus
								receptor homolog [Rattus norvegi
0.002739	4.50737	4.44439	5.47889	0.218718	0.048776	0.067073	CB461169	Transcribed sequences
0.003618	7.02454	6.11085	7.19863	0.035911	0.234515	0.075039	M37974	osteoglycin (osteoinductive factor, mimecan)
0.007258	7.29919	7.80462	7.90756	0.145198	0.007311	0.065739	CK950633	similar to NP_612565.1 kinesin family member 23
								[Homo sapiens]
0.006348	9.11153	10.0777	9.28636	0.01768	0.189202	0.15531	CK848208	similar to XP_524747.1 similar to
								histocompatibility 28 [Pan troglod
0.000656	4.52089	5.16352	5.09881	0.106526	0.017049	0.016545	CB168658	Transcribed locus
0.0004	5.60571	6.28826	6.3913	0.053773	0.063446	0.087055	CB463330	Succinate semialdehyde dehydrogenase
								(NAD(+)-dependent succir
0.002006	4.94446	3.99497	3.79603	0.173649	0.094759	0.123417	CB534503	Transcribed locus, weakly similar
								to XP_519213.1 paraoxonase 2 [
0.009713	10.8281	9.92825	9.33185	0.253205	0.201907	0.221374	NM_175827	chemokine (C—C motif) ligand 5
0.00064	11.0449	7.57803	10.8921	0.258042	0.509224	0.189688	AB008573	MHC class I heavy chain, partial cds,
								clone P5647.6m

Early detection of persistently infected calves is the best method of controlling and eradicating BVDV from infected herds. Current diagnostic tests for BVDV include skin biopsies and serology which do not distinguish acutely infected animals from persistently animals. These PI animals go undetected and continue to propagate virus within the herd.
Current methods of detection also have a high rate of false negatives due to the fact that they are based on mutating viral antigens. Most importantly, current tests cannot detect a pregnant cow/heifer which is carrying a persistently infected calf. The present invention describes a method whereby BVDV can be detected in acutely infected calves, persistently infected calves as well as cows or heifers carrying an infected fetus through the identification of differentially expressed surrogate markers described in Tables 1-9. Surrogate markers can exist as mRNA or protein antigens and allow differentiation of type of BVDV infection. By the methods listed previously persistently infected (PI) calves can be differentiated from acutely infected calves and acutely infected calves can be distinguished from non-infected calves. Heifers and cows carrying PI fetuses can also be distinguished from heifers/cows carrying transiently infected fetuses and cows/heifers carrying PI or TI fetuses can be distinguished from cows/heifers carrying non-infected (normal) calves. The same markers can be used to create therapeutics for treating secondary effects of viral disease and monitoring the anti-viral response in infected cattle. The global approach presented herein will aid the prevention, diagnosis, control and treatment of cattle infected with BVDV as well as other RNA viruses.
While certain of the preferred embodiments of the present invention have been described and specifically exemplified above, it is not intended that the invention be limited to such embodiments. Various modifications may be made thereto without departing from the scope and spirit of the present invention, as set forth in the following claims.

Claims

1. A method for diagnosing BVDV in a ruminant test animal comprising:

a) obtaining a biological sample from a test animal and from a non-BVDV infected animal;

b) contacting said sample with an agent having affinity for at least one differentially expressed BVDV surrogate marker shown in Tables 1-9; and

d) diagnosing the presence of BVDV via detection of at least one differentially expressed BVDV surrogate marker, an alteration in the expression level of said BVDV surrogate marker obtained from said test animal, relative to that obtained from said non-BVDV infected animal being indicative of BVDV in said test animal.

2. The method of claim 1, wherein said at least one BVDV surrogate marker is a nucleic acid and said expression level is up-regulated in response to BVDV infection.

3. The method of claim 1, wherein said at least one BVDV surrogate marker is a nucleic acid and said expression level is down-regulated in response to BVDV infection.

4. The method of claim 1, wherein said at least one BVDV surrogate marker is a nucleic acid immobilized on a gene chip.

5. The method of claim 1, wherein said biological sample is selected from the group consisting of blood, urine, skin, serum, milk, sputumr, saliva, and tears.

6. The method of claim 1 wherein said biological sample comprises blood cells or skin cells which are lysed to release nucleic acids therein.

7. The method of claim 6, wherein said released nucleic acids are amplified.

8. The method of claim 1, wherein said ruminant animal is a persistently infected steer or heifer and at least one BVDV surrogate marker is a nucleic acid which is upregulated and is selected from the group consisting of CK945739, CK777968,NM_—173941 and CK960499. which is upregulated and is selected from the group consisting of CK945739, CK777968, NM_—173941 and CK960499.

9. The method of claim 1, wherein said ruminant animal is a persistently infected steer and at least one BVDV surrogate marker is a nucleic acid which is downregulated and is selected from the group consisting of CK848330, BP 102272, AU278490 and BE723387.

10. The method of claim 1, wherein said ruminant animal is a heifer carrying a persistently infected fetus and at least one BVDV surrogate marker is a nucleic acid which is upregulated and is selected from the group consisting of CK977019, CA923353, CB461169, and CB445920.

11. The method of claim 1, wherein said ruminant animal is a heifer carrying a persistently infected fetus and at least one BVDV surrogate marker is a nucleic acid which is down regulated and is selected from the group consisting of NM_—175827, CB425639, NM_—174511 and CB534503.

12. The method of claim 1, wherein said ruminant animal is a heifer carrying a transiently infected fetus and at least one BVDV surrogate marker is a nucleic acid which is upregulated and is selected from the group consisting of CK960499, CB464371, NM_—174366, and CB433489.

13. The method of claim 1, wherein said ruminant animal is a heifer carrying a transiently infected fetus and at least one BVDV surrogate marker is a nucleic acid which is down regulated and is selected from the group consisting of CB444277, AB008573, CB433789 and AV609250.

14. A gene chip for performing the method of claim 1 comprising a plurality of BVDV surrogate markers selected from the group consisting of CK945739, CK777968, NM_—173941, CK960499, CK848330, BP102272, AU278490, BE1723387, CK977019, CA923353, CB461169, CB445920, NM_—175827, CB425639, NM_—174511, CB534503. CK960499, CB464371, NM_—174366, CB433489, CB444277, AB008573, CB433789 and AV609250.

15. The method of claim 1, wherein said at least one BVDV surrogate marker is a polypeptide and said expression level is up-regulated in response to BVDV infection.

16. The method of claim 1, wherein said at least one BVDV surrogate marker is a polypeptide and said expression level is down-regulated in response to BVDV infection.

17. The method of claim 1, wherein said at least one BVDV surrogate marker is a polypeptide or fragment thereof immobilized on a solid support.

18. The method of claim 1, wherein said ruminant animal is a persistently infected steer and at least one BVDV surrogate marker is a polypeptide or fragments thereof which is upregulated and is selected from the group consisting of polypeptides thereof encoded by CK945739, CK777968, NM_—173941 and CK960499.

19. The method of claim 1, wherein said ruminant animal is a persistently infected steer and at least one BVDV surrogate marker is a polypeptide or fragments thereof which is downregulated and is selected from the group consisting of polypeptides encoded by CK848330, BP102272, AU278490 and BE723387.

20. The method of claim 1, wherein said ruminant animal is a heifer carrying a persistently infected fetus and at least one BVDV surrogate marker is a polypeptide or fragment thereof which is upregulated and is selected from the group consisting of polypeptides encoded by CK977019, CA923353, CB461169, and CB445920.

21. The method of claim 1, wherein said ruminant animal is a heifer carrying a persistently infected fetus and at least one BVDV surrogate marker is a polypeptide or fragment thereof which is down regulated and is selected from the group consisting of polypeptides encoded by NM_—175827, CB425639, NM_—174511 and CB534503.

22. The method of claim 1, wherein said ruminant animal is a heifer carrying a transiently infected fetus and at least one BVDV surrogate marker is a polypeptide or fragment thereof which is upregulated and is selected from the group consisting of polypeptides encoded by CK960499, CB464371, NM_—174366, and CB433489.

23. The method of claim 1, wherein said ruminant animal is a heifer carrying a transiently infected fetus and at least one BVDV surrogate marker is a polypeptide or fragment thereof which is down regulated and is selected from the group consisting of polypeptides encoded by CB444277, AB008573, CB433789 and AV609250.

24. A solid support for performing the method of claim 1 comprising a plurality of BVDV surrogate polypeptide markers selected from the group consisting of polypeptides encoded by CK945739, CK777968, NM_—173941, CK960499, CK848330, BP102272, AU278490, BE723387, CK977019, CA923353, CB461169, CB445920, NM_—175827, CB425639, NM_—174511, CB534503. CK960499, CB464371, NM_—174366, CB433489, CB444277, AB008573, CB433789 and AV609250.

25. The method of claim 1, wherein said ruminant test animal is selected from the group consisting of a bovine a steer, a pregnant bovine, a bovine fetus and a bovine calf.

26. The method of claim 1, wherein said agent having affinity for said BVDV surrogate marker is selected from the group consisting of at least one nucleic acid which specifically hybridizes with at least one nucleic acid shown in Tables 1-9, and an antibody immunologically specific for at least one polypeptide encoded by a nucleic acid shown in Tables 1-9.

27. The method of claim 26, wherein said agent is detectably labeled.

28. A kit for differentially diagnosing BVDV infection via the method of claim 1, comprising at least one BVDV surrogate marker detector molecule, and reagents for detection of the same said optionally comprising a gene chip comprising a plurality of BVDV surrogate markers selected from the group consisting of CK945739, CK777968, NM_173941, CK960499, CK848330, BP102272, AU278490, BE723387, CK977019, CA923353, CB461169, CR445920, NM_—175827, CB425639, NM_—174511, CB534503. CK960499, CB464371, NM_—174366, CB433489, CB444277, AB008573, CB433789 and AV609250 or a solid support comprising a plurality of BVDV surrogate polypeptide markers selected from the group consisting of polypeptides encoded by CK945739, CK777968, NM_—173941, CK960499, CK848330, BP102272, AU278490, BE723387, CK977019, CA923353, CB461169, CB445920, NM_—175827, CB425639, NM_—174511, CB534503. CK960499, CB464371, NM_—174366, CB433489, CB444277, AB008573, CB433789 and AV609250.

29. The kit of claim 28, wherein said BVDV surrogate marker detector molecule is selected from the group consisting of a probe or primer which specifically hybridizes with a BVDV surrogate marker nucleic acid, and an antibody which specifically binds to a BVDV surrogate marker polypeptide.

30. A method as claimed in claim 1 further comprising detection of markers associated with transient or acute BVDV infection.

31. A method for identifying agents useful for the treatment of viral infections, comprising:

a) providing a host cell expressing at least BVDV surrogate marker in Tables 1-9 which is differentially expressed in response to viral infection and exposing said cell to an RNA virus under conditions suitable for infection to occur;

b) incubating said host cells in the presence and absence of said agent; and

c) identifying those agents which modulate the expression of at least one BVDV surrogate marker in treated cells when compared to untreated cells.

32. A method for detecting viral surrogate marker molecules in a test animal comprising:

a) obtaining a plurality of biological samples from said test animal and from a non-virally infected animal;

b) contacting said biological sample with a composition comprising one or more viral surrogate marker molecule detection reagents in an amount effective to permit detection and quantitation of a viral surrogate molecule, if present, in said sample; and

c) determining from b) the amount of said viral surrogate marker molecule, wherein an alteration of levels of said viral surrogate marker molecule, relative to those obtained from non-virally infected animals, is indicative of viral infection in said test animal.

33. The method of claim 32, wherein a lack of alteration of levels of said viral surrogate marker molecule indicates that the test animal is not virally infected.

34. The method of claim 32, wherein said viral surrogate marker molecule is increased in a test subject infected with a virus selected from the group consisting of BVDV, Influenza, HIV, Ebola virus, FcLv, FIP virus, Bluetongue virus, West Nile Virus, hepatitis C Virus and Epizootic Hemorrhagic Disease Virus.